Our Pricing

How Long Before Wegovy Works? Understanding Your Weight Loss Timeline

Understanding how long before Wegovy works is one of the most common questions from patients starting semaglutide treatment. Clinical trials demonstrate that most patients begin experiencing appetite reduction within the first week, with measurable weight loss typically emerging between 4-8 weeks of treatment [1]. At Cured Pharmacy, our UK-registered clinical team guides you through every stage of your Wegovy journey, from initial dosing to long-term maintenance, ensuring you know exactly what to expect and when.

How Long Before Wegovy Works: The Clinical Timeline

When patients ask how long before Wegovy works, the answer depends on which effects we're measuring. Semaglutide begins binding to GLP-1 receptors within hours of your first injection, triggering immediate physiological changes in appetite regulation and gastric emptying [1]. However, the timeline for noticeable weight loss follows a more gradual pattern that aligns with the medication's dose escalation schedule.

The landmark STEP 1 trial, which enrolled 1,961 adults with obesity, provides clear evidence of Wegovy's timeline. Participants experienced an average weight loss of 1% by week 4, 5% by week 12, and 10% by week 20, with peak results of 14.9% total body weight loss achieved at 68 weeks [2]. Most patients report reduced hunger and smaller portion sizes within the first 1-2 weeks, well before significant weight changes appear on the scale.

Individual response varies based on starting BMI, adherence to the dose escalation protocol, and lifestyle factors. Patients with higher baseline weights often see more rapid initial losses, whilst those closer to their target weight may experience a slower but steady trajectory. The key is understanding that Wegovy is designed for gradual, sustainable weight loss rather than rapid drops that often lead to rebound weight gain.

What Happens in Your First Month: Early Signs Wegovy Is Working

Before you see dramatic changes on the scale, your body provides several indicators that Wegovy is working. Within the first 7-10 days at the 0.25mg starter dose, most patients notice reduced food cravings, longer periods between feeling hungry, and an earlier sensation of fullness during meals [3]. These appetite changes are the first clinical sign that semaglutide is engaging GLP-1 receptors in your brain and digestive system.

During weeks 2-4, as you transition to the 0.5mg dose, you may experience what our pharmacist Tarun Kumar describes as 'effortless portion control' — naturally eating less without the psychological battle that characterises traditional dieting. Some patients report mild nausea during this adjustment period, which typically resolves within a few days and actually correlates with better weight loss outcomes in clinical studies [1].

By the end of month one, expect a weight loss of 1-3% of your starting body weight if you're following the prescribed protocol. For a patient starting at 100kg, this translates to 1-3kg — modest but clinically significant, and a strong predictor of continued success. Remember that Wegovy requires clinical assessment by a UK prescriber, and your individual timeline should be discussed with your healthcare provider.

Managing Expectations During the Starter Dose Phase

The 0.25mg and 0.5mg doses are intentionally low to allow your body to adapt to semaglutide whilst minimising gastrointestinal side effects. Some patients worry that Wegovy isn't working during this phase because weight loss is modest. However, these starter doses are building the foundation for more significant results at higher doses. The STEP trials showed that patients who completed the full dose escalation achieved substantially better outcomes than those who remained at lower doses [2].

Track non-scale victories during your first month: reduced snacking frequency, smaller restaurant portions, decreased alcohol cravings, and improved energy levels. These behavioural changes are powerful indicators that Wegovy is reshaping your relationship with food, even before dramatic weight changes occur.

Months 2-4: When Wegovy Results Accelerate

Understanding how long before Wegovy works at therapeutic doses is crucial for maintaining motivation. As you progress through 1mg (week 9), 1.7mg (week 13), and finally reach the maintenance dose of 2.4mg at week 17, weight loss typically accelerates [3]. The STEP 1 trial documented that the steepest weight loss gradient occurred between weeks 12-28, when most participants had reached or were approaching the full 2.4mg dose [2].

During this period, patients at Cured Pharmacy commonly report losing 1-2kg per week, though this varies significantly based on individual metabolism, adherence, and concurrent lifestyle modifications. By month 4 (week 16), average weight loss in clinical trials reached approximately 8-10% of starting body weight. For our 100kg example patient, this represents 8-10kg — a substantial, visible change that often motivates continued treatment.

This acceleration phase is also when Wegovy's metabolic benefits beyond weight loss become apparent. Clinical studies show improvements in HbA1c levels, blood pressure, and lipid profiles emerging around the 12-16 week mark [1]. These cardiometabolic improvements occur even in patients who haven't yet reached their target weight, demonstrating that Wegovy works on multiple physiological pathways simultaneously.

Optimising Your Results During Dose Escalation

Whilst Wegovy is highly effective as monotherapy, combining it with structured lifestyle changes amplifies results. The STEP 1 trial participants received counselling on a reduced-calorie diet and increased physical activity, contributing to their exceptional outcomes [2]. At Cured Pharmacy, we recommend focusing on protein intake (1.2-1.6g per kg body weight) to preserve lean muscle mass during weight loss, and incorporating resistance training 2-3 times weekly.

Hydration becomes increasingly important as Wegovy slows gastric emptying. Aim for 2-3 litres of water daily, spacing it between meals rather than drinking large amounts with food, which can exacerbate feelings of fullness or nausea. If you experience persistent side effects that interfere with dose escalation, consult your prescriber about temporarily remaining at your current dose before advancing.

Long-Term Timeline: How Long Before Wegovy Works at Maximum Effectiveness

The question of how long before Wegovy works at its full potential is answered by the STEP trial's 68-week endpoint. Participants reached peak weight loss at approximately 60-68 weeks, with an average reduction of 14.9% total body weight compared to 2.4% in the placebo group [2]. This timeline underscores that Wegovy is designed for sustained, gradual weight loss rather than rapid results.

After reaching the 2.4mg maintenance dose at week 17, weight loss continues but at a decelerating rate. Most patients experience their most rapid losses between weeks 20-40, followed by a plateau phase where weight stabilises. This plateau doesn't indicate treatment failure — it represents your body reaching a new equilibrium at a healthier weight. Clinical data shows that patients who continue Wegovy during this plateau maintain their weight loss, whilst those who discontinue typically regain 7% within one year [4].

At Cured Pharmacy, we've observed that patients who remain on Wegovy for 12+ months achieve the most durable results. The medication's effects on appetite regulation and metabolic function require ongoing support; semaglutide works by continuously activating GLP-1 receptors, and these effects diminish when treatment stops. For chronic weight management, Wegovy should be viewed as a long-term intervention, similar to medications for hypertension or diabetes.

Factors That Influence How Quickly Wegovy Works for You

Individual variation in how long before Wegovy works stems from several physiological and behavioural factors. Baseline insulin resistance significantly impacts response time — patients with higher fasting insulin levels or diagnosed type 2 diabetes may experience slower initial weight loss but often achieve excellent results with continued treatment [3]. Your genetic makeup also plays a role; variations in GLP-1 receptor genes can influence both efficacy and side effect profiles.

Adherence to the dosing schedule is perhaps the most controllable factor affecting timeline. Wegovy must be injected once weekly, ideally on the same day each week, to maintain stable semaglutide levels. Missing doses or inconsistent timing can delay results and increase side effects when resuming. The medication's half-life of approximately 7 days means that skipping even one injection reduces therapeutic levels significantly [1].

Concurrent medications can also affect how quickly Wegovy works. Drugs that slow gastric emptying (like certain diabetes medications) may intensify Wegovy's effects, whilst medications that increase appetite (such as some antidepressants or corticosteroids) may partially counteract them. Always inform your prescriber of all medications and supplements you're taking. At Cured Pharmacy, our clinical assessment process identifies potential interactions before treatment begins.

Age, Gender, and Metabolic Differences

STEP trial subgroup analyses revealed that women and men experienced similar percentage weight loss, though women reported slightly higher rates of nausea [2]. Older adults (65+) achieved comparable efficacy to younger participants but required more careful monitoring for side effects and potential drug interactions. Patients with previous weight loss surgery showed variable responses, with some achieving excellent results and others experiencing blunted effects, likely due to altered GLP-1 physiology post-surgery.

Metabolic rate, influenced by age, muscle mass, and thyroid function, affects how quickly Wegovy produces visible results. Two patients losing the same percentage of body weight may see different timeline results based on starting weight — a 5% loss appears more dramatic on someone weighing 80kg than 120kg, even though the metabolic benefit is equivalent.

Switching to Wegovy: How Long Before You See Results After Changing Treatments

Patients switching from other weight loss medications to Wegovy often ask how long before Wegovy works compared to their previous treatment. If you're transitioning from Saxenda (liraglutide), another GLP-1 receptor agonist, you'll likely notice Wegovy's effects more quickly because your body is already adapted to GLP-1 stimulation. Most Saxenda-to-Wegovy switchers report enhanced appetite suppression within 1-2 weeks, as semaglutide has a longer half-life and greater GLP-1 receptor affinity than liraglutide [1].

Switching from Mounjaro (tirzepatide) to Wegovy represents a different scenario. Tirzepatide activates both GLP-1 and GIP receptors, whilst semaglutide targets only GLP-1. Some patients transitioning from Mounjaro to Wegovy experience slightly reduced appetite suppression initially, though this typically normalises within 2-4 weeks as semaglutide reaches steady-state levels. Clinical trials haven't directly compared switching outcomes, but real-world evidence suggests most patients maintain their weight loss when transitioning between these medications under medical supervision [3].

For patients moving from non-GLP-1 treatments like Orlistat or Mysimba, the timeline mirrors that of treatment-naïve patients. You'll need to complete the full dose escalation protocol starting at 0.25mg, with initial appetite changes appearing within 1-2 weeks and measurable weight loss emerging around week 4-8. At Cured Pharmacy, we offer Wegovy from £69.00, making it one of the most cost-effective GLP-1 options in the UK, and our clinical team provides guidance throughout your transition to ensure continuity of care.

Managing the Transition Period

When switching medications, timing matters. If transitioning from Saxenda, stop liraglutide injections and begin Wegovy within 24-48 hours to avoid a gap in GLP-1 receptor stimulation. For Mounjaro-to-Wegovy switches, your prescriber may recommend starting Wegovy at a higher initial dose (0.5mg or 1mg) rather than 0.25mg, depending on your current tirzepatide dose and tolerance. Never adjust dosing protocols without prescriber approval.

Monitor for side effects during transitions, as switching between GLP-1 medications can temporarily increase nausea or gastrointestinal symptoms. These typically resolve within one week as your body adjusts. Keep a symptom diary during your first month on Wegovy to help your healthcare provider optimise your treatment plan. Subject to prescriber approval, dose adjustments can be made to balance efficacy with tolerability.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
2. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.